Anne S Abel1, Arseniy P Yashkin, Frank A Sloan, Michael S Lee. 1. Departments of Ophthalmology and Visual Neurosciences (ASA, MSL), Neurology (MSL), and Neurosurgery (MSL), University of Minnesota, Minneapolis, Minnesota; and Department of Economics (APY, FAS), Duke University, Durham, North Carolina.
Abstract
BACKGROUND: To determine if Type 2 diabetes mellitus (DM) is protective against giant cell arteritis (GCA) and to estimate the incidence of GCA diagnosis from Medicare claims. METHODS: Medicare 5% claims files from 1991 to 2011 were used to identify beneficiaries diagnosed with DM, but not GCA, within a 3-year ascertainment period. Propensity score matching was used to define a control group of nondiabetics with comparable demographic covariates. Competing risk regression was then used to assess the impact of DM diagnosis on GCA diagnosis. To allow for a 3-year ascertainment period, the analysis sample was limited to beneficiaries older than 68 years at baseline. RESULTS: A total of 151,041 beneficiaries diagnosed with DM were matched to an equal number of controls. Mean study follow-up was 67.75 months. GCA was diagnosed among 1116 beneficiaries with DM (0.73%) vs 465 (0.30%) controls. The risk of receiving a GCA diagnosis among patients with DM was increased by 100% (subhazard ratio, 2.00; 95% confidence interval, 1.78-2.25). The annual incidence of GCA diagnosis among claims for US Medicare beneficiaries older than 68 years old was 93 in 100,000. CONCLUSIONS: A DM diagnosis is not protective against a GCA diagnosis in the Medicare population. Our data suggest that a DM diagnosis increases the risk of GCA diagnosis within 5.7 years for Medicare beneficiaries older than 68 years.
BACKGROUND: To determine if Type 2 diabetes mellitus (DM) is protective against giant cell arteritis (GCA) and to estimate the incidence of GCA diagnosis from Medicare claims. METHODS: Medicare 5% claims files from 1991 to 2011 were used to identify beneficiaries diagnosed with DM, but not GCA, within a 3-year ascertainment period. Propensity score matching was used to define a control group of nondiabetics with comparable demographic covariates. Competing risk regression was then used to assess the impact of DM diagnosis on GCA diagnosis. To allow for a 3-year ascertainment period, the analysis sample was limited to beneficiaries older than 68 years at baseline. RESULTS: A total of 151,041 beneficiaries diagnosed with DM were matched to an equal number of controls. Mean study follow-up was 67.75 months. GCA was diagnosed among 1116 beneficiaries with DM (0.73%) vs 465 (0.30%) controls. The risk of receiving a GCA diagnosis among patients with DM was increased by 100% (subhazard ratio, 2.00; 95% confidence interval, 1.78-2.25). The annual incidence of GCA diagnosis among claims for US Medicare beneficiaries older than 68 years old was 93 in 100,000. CONCLUSIONS: A DM diagnosis is not protective against a GCA diagnosis in the Medicare population. Our data suggest that a DM diagnosis increases the risk of GCA diagnosis within 5.7 years for Medicare beneficiaries older than 68 years.
Authors: S T Normand; M B Landrum; E Guadagnoli; J Z Ayanian; T J Ryan; P D Cleary; B J McNeil Journal: J Clin Epidemiol Date: 2001-04 Impact factor: 6.437
Authors: Miguel A Gonzalez-Gay; Angela Piñeiro; Adriana Gomez-Gigirey; Carlos Garcia-Porrua; Robustiano Pego-Reigosa; Trinidad Dierssen-Sotos; Javier Llorca Journal: Medicine (Baltimore) Date: 2004-11 Impact factor: 1.889
Authors: M Fröhlich; A Imhof; G Berg; W L Hutchinson; M B Pepys; H Boeing; R Muche; H Brenner; W Koenig Journal: Diabetes Care Date: 2000-12 Impact factor: 19.112
Authors: S T Garrity; M Pistilli; M S Vaphiades; N Q Richards; P S Subramanian; P R Rosa; B L Lam; B J Osborne; G T Liu; K E Duncan; R K Shin; N J Volpe; K S Shindler; M S Lee; M L Moster; E H Tracey; S E Cuprill-Nilson; M A Tamhankar Journal: Eye (Lond) Date: 2016-09-16 Impact factor: 3.775
Authors: Karin Wadström; Lennart Jacobsson; Aladdin J Mohammad; Kenneth J Warrington; Eric L Matteson; Carl Turesson Journal: Rheumatology (Oxford) Date: 2020-11-01 Impact factor: 7.580